To order this 270+ page report, please visit https://www.rootsanalysis.com/reports/digital-biomarkers-market.html
Key Inclusions
§
An overview of the
current market landscape of digital solutions for biomarkers, including
information on current status (approved, marketed, USFDA submission,
research and development, proof-of-concept, and discovery), content of
solution (combination offering of
software application / gaming solution + AI support or device or
personal coach, and standalone software / gaming solution ), purpose of
solution (diagnosis, early screening, monitoring and predictive insights),
type of biomarker (cognitive, idiosyncratic, molecular, neurophysiological,
physiological, respiratory, vocal, and others ), target indication(s), therapeutic
area(s), target population, and prescription requirement. In addition, it
highlights the companies engaged in developing digital solutions for
biomarkers, along with information on their year of establishment, company
size, type of business model used (B2B and B2C) and location of
headquarters.
§ An in depth analysis of the contemporary market
trends, presented using five schematic representations, including [A] a bubble
analysis comparing the leading players engaged in the development of digital
solutions for biomarkers, based on various parameters (such as product
portfolio strength, type of biomarker and company size), [B] a grid
representation illustrating the distribution of digital solutions for
biomarkers based on their current status, content of solution and target
therapeutic area, [C] an insightful tree map representation of digital
solutions for biomarkers based on their therapeutic area and company size, [D]
a world map representation highlighting the regional distribution of developer
companies, and [E] a comparative grid representation to highlight the current
and likely future market landscape based on status of development, type of
biomarker and therapeutic area.
§ Elaborate profiles of prominent players that
are either currently engaged in developing or have developed digital solutions
for biomarkers. Each company profile features a brief overview of the company (with
information on its year of establishment, number of employees, location of
headquarters and key members of the executive team), details related to
their respective product portfolios, recent developments and an informed future
outlook.
§ A detailed product competitiveness analysis of
digital solutions for biomarkers taking into consideration several relevant
parameters, such as current status, content of solution, purpose of solution,
therapeutic area, and prescription requirement.
§ An analysis of the recent global events (summits
/ forums / conferences / annual meetings) that were organized for
stakeholders engaged in this domain, highlighting the evolution of discussion
topics related to digital solutions for biomarkers. The chapter also includes
details on type of event, regional distribution, emerging agendas, popular
organizers, and most active industry and non-industry players.
§ An elaborate analysis of the investments,
including seed financing, venture capital financing, debt financing, grants /
awards, made at various stages of development in companies that are engaged in
this field, during the period 2012-2020 (till September).
§ An analysis of the partnerships that have been
inked by stakeholders in this domain, in the period between 2014 and 2020 (till
September), covering marketing and distribution agreements, mergers /
acquisitions, pilot programs, product / technology integration agreements,
product / technology licensing agreements, product development agreements,
product development and commercialization agreements, product evaluation
agreements, and research and development agreements.
§ An analysis of the various digital solutions
for biomarkers focused initiatives carried out by big pharma players (out of
top 25 established pharmaceutical players), featuring [A] an analysis
highlighting information on clinical research activity, funding, partnership
activity, research publications, and participation in conferences, and [B] a
spider web representation of the individual competitiveness of the initiatives
of big pharma players based on multiple relevant parameters.
§
An insightful
discussion on how the recent COVID-19 pandemic is likely to impact the overall
digital solutions for biomarkers market, along with information on the key
initiatives undertaken by big pharma players to overcome the challenges faced
due to the pandemic.
The report also features the likely distribution
of the current and forecasted opportunity across important market segments,
mentioned below:
§ Content
of Solution
§
Software Application + AI Support
§
Software Application + Device
§
Standalone Software Application
§
Other Contents of Solutions
§ Purpose
of Solution
§ Diagnosis
§ Early
Screening
§ Monitoring
§ Predictive
Insights
§ Type
of Biomarker
§ Cognitive
Biomarkers
§ Idiosyncratic
Biomarkers
§ Physiological
Biomarkers
§ Vocal
Biomarkers
§ Other
Biomarkers
§ Therapeutic
Areas
§ Autoimmune
Disorders
§ Cardiovascular
Disorders
§ Infectious
Disorders
§ Mental
Health Problems
§ Neurological
Disorders
§ Respiratory
Disorders
§ Substance
Use Disorders
§ Others
§ Business
Model
§ Business
to Business (Healthcare Providers, Payers, Employers and
Pharmaceutical Companies)
§ Business
to Consumer (Patients and Caregivers)
§ Key
Geographical Regions
§ North
America
§ Europe
§ Asia-Pacific
§ Middle
East and North Africa (MENA)
§ Rest
of the world
The report includes
detailed transcripts of discussions held with the following experts:
§ Edouard
Gasser (Co-Founder and Chief Executive Officer, Tilak Healthcare)
§ Michael
Seggev (Chief
Commercial Officer, Vocalis
Health)
To request sample pages, please visit https://www.rootsanalysis.com/reports/digital-biomarkers-market/request-sample.html
Key Questions Answered
§ Who are the leading players engaged in the
development of digital solutions for biomarkers?
§ Which are the popular therapeutic areas where digital
biomarkers are currently relevant?
§ What kind of global level events related to
digital biomarkers, have been organized in the recent past?
§ What is the trend of capital investments in the
digital biomarkers market?
§ Which partnership models are most commonly
adopted by stakeholders in this industry?
§ What is the tole of big pharma players engaged
in this domain?
§ How has the COVID-19 pandemic impacted the
digital biomarkers market?
§ What are the opportunities available for
digital solutions for biomarkers in emerging markets?
§ How is the current and future opportunity
likely to be distributed across key market segments?
§ What are the anticipated future trends related
to digital solutions for biomarkers market?
You may also be
interested in the following titles:
1.
AI-based Drug
Discovery Market: Focus on Deep Learning and Machine Learning, 2020-2030
2.
Connected / Smart Drug
Delivery Systems Market by Product Type (Connected Inhalers, Connected
Autoinjectors, Connected Pen injectors, Connected Wearable Injectors, Add-On
Sensors and Others), Therapeutic Area (Metabolic Disorders, Neurological
Disorders, Respiratory Disorders and Others) and Key Geographical Regions
(North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the
World): Industry Trends and Global Forecasts, 2020-2030
3.
Diabetes Monitoring
Devices Market by Type of Device (Self-Monitoring Blood Glucose Devices and
Continuous Blood Glucose Monitoring Devices), Diabetes Type (Type 1 Diabetes
and Type 2 Diabetes), Type of Self-Monitoring Blood Glucose Device Component
(Lancing Devices, Blood Glucose Meters and Testing Strips), Type of Continuous
Blood Glucose Monitoring Device Component (Sensors, Transmitters and
Receivers), and Key Geographies: Industry Trends and Global Forecasts,
2020-2030
Contact Us
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
